Baricitinib (Olumiant)

CADTH recommends that Olumiant be reimbursed by public drug plans for the treatment of adults with severe alopecia areata (AA) if certain conditions are met. Olumiant should only be covered to treat adults who have severe AA with at least 50% loss in scalp hair. The current AA episode should have already lasted for more than 6 months and less than 8 years. Olumiant should only be reimbursed if prescribed by a dermatologist with expertise managing patients with severe AA and if the cost is reduced. Olumiant should not be used in combination with other Janus kinase (JAK) inhibitors, biologic immunomodulators, or systemic immunosuppressants. Olumiant should only be reimbursed for 36 weeks when first prescribed. If a patient continues to experience improvements, reimbursement of Olumiant can be extended every 12 months.